Abstract

Commercial priorities have been identified as negative factors in drug development. We trace the problem to inattention to sound clinical pharmacology practices. When properly applied, clinical pharmacology and associated drug development sciences can, hand in hand, facilitate success in commercial drug development.

Keywords: Clinical Pharmacology, Alzheimer Disease, Drug Development, acetylcholinesterase (AChE) inhibition, cytoplasmic AChE